<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587129</url>
  </required_header>
  <id_info>
    <org_study_id>201801</org_study_id>
    <nct_id>NCT03587129</nct_id>
  </id_info>
  <brief_title>Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer</brief_title>
  <official_title>Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with &quot;Platinum-resistant recurrent ovarian cancer&quot; after second-line
      chemotherapy failure Using apatinib as a single drug Clinical efficacy observation Single
      study no control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall 5-year survival rate of ovarian cancer is 45%. The mortality rate of ovarian
      cancer accounts for the first in gynecologic cancer deaths. Ovarian cytoreductive surgery and
      postoperative platinum based chemotherapy are the standard treatment for advanced ovarian
      cancer. About 80% of ovarian cancer will eventually show relapse and metastasis. All patients
      with recurrent ovarian cancer will eventually develop into &quot;platinum resistance&quot;. Platinum
      resistance was found in 1-6 months with platinum-free interval. There is no standard
      treatment protocol for recurrent ovarian cancer of &quot;platinum resistant,&quot; usually with
      platinum-free single chemotherapy, such as: paclitaxel, docetaxel, liposomal doxorubicin,
      gemcitabine, topotecan and other. The response rate was 10%-30%, the median progression free
      survival was &lt;4 months, and the median overall survival time was 12 months with platinum-free
      single-agent chemotherapy. The incidence of grade 3-4 hematologic or non-hematologic toxicity
      is about 40%. And chemotherapy has 14% mortality rate within 30 days of the start of
      single-agent chemotherapy in the literature reported. VEGF plays an important role in
      invasion and metastasis of ovarian cancer. VEGF directly stimulates tumor cell proliferation,
      growth and migration, and promotes ovarian cancer metastasis. The growth and metastasis of
      ovarian cancer cells are related to the quantity of VEGF. It has confirmed that inhibition of
      VEGF function can inhibit angiogenesis and inhibit the growth and metastasis of ovarian
      cancer cells in vivo experiments. The Chinese State Food and Drug Administration approved
      small molecular targeting drug, apatinib, for the treatment of advanced gastric cancer, for
      approval in December 13, 2014. The role of apatinib is the intracellular ATP binding site of
      VEGFR2 tyrosine receptor, which blocks the signal transduction of VEGF binding and leads to
      tumor angiogenesis inhibition. Apatinib can inhibit VEGFR2 effectively at a very low
      concentration, and a higher concentration can inhibit the platelet derived growth factor
      receptor (PDGFR), c-Kit and c-Src. Apatinib has only 20% grade 3-4 hematological and non
      hematological toxicity in the treatment of metastatic gastric cancer and gastro-esophageal
      junction adenocarcinoma. Deng et al reported one cases of progressive ovarian cancer. After
      4-line chemotherapy resistance, a daily oral apatinib 500 mg was taken and a longer
      progression free survival (11.3 months) was obtained. Xie Congying et al of the First
      Affiliated Hospital of Wenzhou Medical University had a report in the 2017 ESMO conference.
      The report reviewed 15 cases of recurrent and metastatic ovarian cancer with a single drug
      atapatinib in the treatment of more than 2 lines of chemotherapeutic drug resistance. The
      median progression free survival was 5 months, the objective remission rate was 53.3% and the
      disease control rate was 73.3%. It is known from the above reports that apatinib has good
      efficacy and low toxicity in the treatment of &quot;platinum resistant&quot; recurrent ovarian cancer,
      but there is lack of prospective study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">July 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective remission rate, ORR</measure>
    <time_frame>3 years</time_frame>
    <description>Complete remission (CR) + partial remission (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression- free survival, PFS</measure>
    <time_frame>3 years</time_frame>
    <description>from entry time to disease progression or any cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade 3-4 hematologic or non hematologic toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>defined by CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>from entry time to death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate, DCR</measure>
    <time_frame>3 years</time_frame>
    <description>Complete remission (CR) + partial remission (PR) + disease stability (SD)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 times a day, atapinib, 500 mg, is taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>An anti-tumor Targeted drug</description>
    <arm_group_label>apatinib</arm_group_label>
    <other_name>Apatinib mesylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, age ≥18 years, signed informed consent.

          2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          3. Patients must have a life expectancy of at least 3 months.

          4. Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the
             ovary. Failure of at least two-line chemotherapy OR platinum resistant ovarian cancer
             (defined as relapsing within 6 months after a platinum based chemotherapy) OR platinum
             refractory ovarian cancer (defined as progressing during a platinum based
             chemotherapy).

          5. Criteria for recurrence or metastasis: blood CA125 is more than 2 times the upper
             limit of normal value, or imaging findings (CT/MRI/PET-CT) show recurrence or
             metastasis, or ascites cancer cells are positive.

          6. Platinum refractory or resistant criteria: relapse or metastasis within 6 months end
             of platinum based chemotherapy.

          7. The interval time to last chemotherapy was more than 4 weeks.

          8. The patient received radiotherapy or surgery for more than 4 weeks, and the wound
             healed completely.

          9. Patients must have adequate organ function as defined by the following criteria: White
             blood cell count ≥ 3 x 10^9/L, Absolute neutrophil count (ANC) (≥ 1.0 x 10^9/L),
             Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10^9/L. Total bilirubin ≤ 1 x upper limit of
             normal (ULN), AST and ALT ≤ 2 x ULN. Serum creatinine ≤ 1 x ULN

         10. The main organs (liver, kidney and heart) function are basically normal.

        Exclusion Criteria:

          1. Had prior exposure to apatinib or has known allegies to apatinib.

          2. History of other malignant tumors (except those with cured basal cell carcinoma and
             cervical carcinoma in situ).

          3. History of myocardial infarction, or unstable angina, or New York Heart Association
             (NYHA) Grade III-IV within 6 months prior to Day 1.

          4. Patients with QT interval prolongation.

          5. Inadequately controlled hypertension.

          6. Serious, non-healing wound, active ulcer, bowel obstruction.

          7. History of abdominal fistula or gastrointestinal perforation within 28 days prior to
             Day 1.

          8. Evidence of bleeding diathesis or coagulopathy.

          9. Patients with positive urine protein.

         10. Major surgical procedure within 28 days prior to Day 1.

         11. Symptomatic central nervous system (CNS) metastasis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZhiPing Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ZhiPing Liu, MD</last_name>
    <phone>+86-13936034546</phone>
    <email>as150001@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liu</last_name>
    <phone>+86045185552350</phone>
    <email>kykbgs123@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu</last_name>
      <phone>+86045185552350</phone>
      <email>kykbgs123@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhao</last_name>
      <phone>+86045185552350</phone>
      <email>kykbgs123@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://seer.cancer.gov/.</url>
    <description>Surveillance, Epidemiology, and End Results program.</description>
  </link>
  <results_reference>
    <citation>Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106.</citation>
    <PMID>12826431</PMID>
  </results_reference>
  <results_reference>
    <citation>Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M; Southwest Oncology Group. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 2008 Jan;108(1):90-4. Epub 2007 Oct 18.</citation>
    <PMID>17949799</PMID>
  </results_reference>
  <results_reference>
    <citation>Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. Review.</citation>
    <PMID>28444622</PMID>
  </results_reference>
  <results_reference>
    <citation>Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Dec 10;32(35):4025.</citation>
    <PMID>24637997</PMID>
  </results_reference>
  <results_reference>
    <citation>Rustin G, Vergote I, Micha JP, Duska LR, Reed N, Bendell J, Spitz D, Dark G, Hoch U, Tagliaferri M, Hannah AL, Garcia AA. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2017 Nov;147(2):276-282. doi: 10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19.</citation>
    <PMID>28935273</PMID>
  </results_reference>
  <results_reference>
    <citation>Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047. Epub 2017 Jun 8.</citation>
    <PMID>28596446</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.</citation>
    <PMID>25366685</PMID>
  </results_reference>
  <results_reference>
    <citation>Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Ovarian cancer. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. Epub 2006 Oct 2. Review.</citation>
    <PMID>17018256</PMID>
  </results_reference>
  <results_reference>
    <citation>Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63.</citation>
    <PMID>17105988</PMID>
  </results_reference>
  <results_reference>
    <citation>Webber K, Friedlander M. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:126-138. doi: 10.1016/j.bpobgyn.2016.11.004. Epub 2016 Nov 23. Review.</citation>
    <PMID>28027849</PMID>
  </results_reference>
  <results_reference>
    <citation>Davis A, Tinker AV, Friedlander M. &quot;Platinum resistant&quot; ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014 Jun;133(3):624-31. doi: 10.1016/j.ygyno.2014.02.038. Epub 2014 Mar 4. Review.</citation>
    <PMID>24607285</PMID>
  </results_reference>
  <results_reference>
    <citation>Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005 May;5(5):355-66. Review.</citation>
    <PMID>15864277</PMID>
  </results_reference>
  <results_reference>
    <citation>Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai XG, Niwa O, Tsujimura T, Sato B, Terano H, Fujiwara H, Hamaoka T. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res. 1996 Sep;87(9):963-71.</citation>
    <PMID>8878460</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16.</citation>
    <PMID>26884585</PMID>
  </results_reference>
  <results_reference>
    <citation>Deng L, Wang Y, Lu W, Liu Q, Wu J, Jin J. Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report. Onco Targets Ther. 2017 Mar 13;10:1521-1525. doi: 10.2147/OTT.S126471. eCollection 2017.</citation>
    <PMID>28352185</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epithelial ovarian cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>platinum-resistant</keyword>
  <keyword>platinum-refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators have no other clinical trial about ovarian cancer</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

